آنژیوژنز در سلامت و بیماری: نقش فاکتور رشد اندوتلیوم عروقی

نوع مقاله : مقاله مروری

نویسندگان

1 دانشجوی کارشناسی ارشد، کمیته‌ی تحقیقات دانشجویی، گروه فیزیولوژی، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

2 دانشجوی دکتری، گروه آناتومی، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی تهران، تهران، ایران

3 دانشیار، گروه فیزیولوژی، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

چکیده

مقدمه: آنژیوژنز به تشکیل عروق خونی جدید از عروق موجود اطلاق می‌شود. این پدیده در شرایط پاتوفیزیولوژیکی مثل رتینوپاتی و نفروپاتی دیابتی، آترواسکلروز، اندومتریوز، هیپرتانسیون و رشد تومور دیده می‌شود. در حالی که آنژیوژنز در شرایط فیزیولوژیک در ترمیم زخم، تخمک‌گذاری و سیکل‌‌های قاعدگی روی می‌دهد. فرایند آنژیوژنز به تعادل بین فاکتور‌های تحریک‌کننده و مهارکننده‌ی آنژیوژنز بستگی دارد. فاکتور کلیدی مؤثر در تکثیر و مهاجرت سلول‌‌های اندوتلیال که اساس تشکیل هر رگ جدیدی است فاکتور رشد اندوتلیوم عروقی (Vascular Endothelial Growth Factor یا VEGF) است. استراتژی آنژیوژنز درمانی شامل مهار آنژیوژنز غیرطبیعی در مواردی هم‌چون دیابت و تومور و تحریک آنژیوژنز در بیماری‌های ایسکمیک قلبی یا بیماری‌‌های عروق محیطی یک روش جدید درمانی محسوب می‌گردد. در این مقاله‌ی مروری ابتدا به آنژیوژنز در شرایط فیزیولوژیک و عوامل مؤثر بر آن به خصوص VEGF و سپس نقش آن در برخی بیماری‌ها پرداخته شده است

کلیدواژه‌ها

عنوان مقاله [English]

Angiogenesis in Health and Disease: Role of Vascular Endothelial Growth Factor (VEGF)

نویسندگان [English]

  • Ensieh Salehi 1
  • Fateme Sadat Amjadi 2
  • Majid Khazaei 3
1 MSc Student of Physiology, Student Research Committee, Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
2 PhD Student in Reproductive Biology, Department of Anatomy, School of Medicine, Tehran University of Medical Sciences,Tehran,Iran.
3 Associate Professor, Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
چکیده [English]

Background: Angiogenesis is the formation of new blood vessels from pre-existing ones. It contributes to physiological and pathophysiological conditions. Pathophysiological angiogenesis is associated with several long-term complications of disease such as diabetic retinopathy and nephropathy, endometriosis, hypertension and tumor development while physiological angiogenesis is involved in wound healing, ovulation and menstrual cycles. The process of angiogenesis depends on the balance of many stimulating or inhibiting factors. The key factor that regulates proliferation and migration of endothelial cells is the Vascular Endothelial Growth Factor (VEGF). Angiogenic therapy includes inhibition of abnormal angiogenesis in some conditions such as tumors or diabetes and stimulation of angiogenesis in conditions of ischemia, such as in ischemic heart disease or peripheral vascular disease. In this review, the mechanism of angiogenesis and role of VEGF during physiological and pathological conditions will be reviewed.Keywords:

کلیدواژه‌ها [English]

  • Angiogenesis
  • VEGF
  • Pathophysiology
  • Endothelium

مراجع

  1. Karamysheva AF. Mechanisms of angiogenesis. Biochemistry (Mosc) 2008; 73(7): 751-62.
  2. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al. Synergistic effect of vascular endothelial growth factor and basic fi-broblast growth factor on angiogenesis in vivo. Circulation 1995; 92(9 Suppl): II365-71.
  3. Carmeliet P, Luttun A. The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis.ThrombHaemost 2001; 86(1): 289-97.
  4. van RN, Piek JJ, Schaper W, Bode C, Busch-mann I. Arteriogenesis: mechanisms and modu-lation of collateral artery development. J Nu-clCardiol 2001; 8(6): 687-93.
  5. Risau W. Mechanisms of angiogenesis. Nature 1997; 386(6626): 671-4.
  6. Douglas NC, Nakhuda GS, Sauer MV, Zimmer-mann RC. Angiogenesis and Ovarian Function. Fertility and Reproduction 2005; 15(4): 7-15.
  7. Li ww, Tsakayannis D, Li VW. Angiogenesis: A control point for normal and delayed wound healing. Contemporary Surgery 2003; (Asup-plement to contemporary surgery): 5-11.
  8. Tomanek RJ, Schatteman GC. Angiogenesis: new insights and therapeutic potential. Anat Rec 2000; 261(3): 126-35.
  9. Lloyd PG, Yang HT, Terjung RL. Arteriogenesis and angiogenesis in rat ischemic hindlimb: role of nitric oxide. Am J Physiol Heart CircPhysiol 2001; 281(6): H2528-38.
  10. Waltenberger J. VEGF resistance as a molecular basis to explain the angiogenesis paradox in dia-betes mellitus. BiochemSoc Trans 2009; 37(Pt 6): 1167-70.
  11. Liekens S, De CE, Neyts J. Angiogenesis: regula-tors and clinical applications. BiochemPharma-col 2001; 61(3): 253-70.
  12. Jayasankar V, Woo YJ, Bish LT, Pirolli TJ, Chat-terjee S, Berry MF, et al. Gene transfer of hepatocyte growth factor attenuates postinfarc-tion heart failure. Circulation 2003; 108 Suppl 1: II230-6.
  13. Kwak HJ, So JN, Lee SJ, Kim I, Koh GY. Angio-poietin-1 is an apoptosis survival factor for en-dothelial cells. FEBS Lett 1999; 448(2-3): 249-53.
  14. Keane MP, Strieter RM. The role of CXC chem-okines in the regulation of angiogene-sis.ChemImmunol 1999; 72: 86-101.
  15. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogen-esis and chronic inflammation. FASEB J 1997; 11(6): 457-65.
  16. Badet J. Angiogenin, a potent mediator of angi-ogenesis. Biological, biochemical and structural properties.PatholBiol (Paris) 1999; 47(4): 345-51.
  17. Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall in-tegrity. Cytokine Growth Factor Rev 1997; 8(1): 21-43.
  18. Schnaper HW, McGowan KA, Kim-Schulze S, Cid MC. Oestrogen and endothelial cell angio-genic activity. ClinExpPharmacolPhysiol 1996; 23(3): 247-50.
  19. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995; 376(6540): 517-9.
  20. Dimmeler S, Hermann C, Galle J, Zeiher AM. Upregulation of superoxide dismutase and nitric oxide synthase mediates the apoptosis-suppressive effects of shear stress on endothelial cells. ArteriosclerThrombVascBiol 1999; 19(3): 656-64.
  21. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth fac-tor. Physiol Rev 1999; 79(4): 1283-316.
  22. Cao Y. Therapeutic potentials of angiostatin in the treatment of cancer.Haematologica 1999; 84(7): 643-50.
  23. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88(2): 277-85.
  24. Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dynamic balance of stimulators and inhibitors. ThrombHaemost 1997; 78(1): 672-7.
  25. Moses MA, Wiederschain D, Wu I, Fernandez CA, Ghazizadeh V, Lane WS, et al. Troponin I is present in human cartilage and inhibits angio-genesis. ProcNatlAcadSci U S A 1999;96(6): 2645-50.
  26. Volpert OV, Fong T, Koch AE, Peterson JD, Wal-tenbaugh C, Tepper RI, et al. Inhibition of angi-ogenesis by interleukin 4. J Exp Med 1998 21; 188(6): 1039-46.
  27. Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, et al. VEGI, a novel cytokine of the tumor ne-crosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 1999; 13(1): 181-9.
  28. Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, et al. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. ProcNatlAcadSci U S A 1999; 96(4): 1246-51.
  29. Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev 2003; 23(2): 117-45.
  30. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13(1): 9-22.
  31. Himadri R. Vascular Endothelial Growth Factors (VEGFs) ;Role in perivascular Therapeutic A ngiogenesis and Diabetic macrovascular Disease. Kuopio: University of Kuopio; 2006.
  32. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular en-dothelial growth factor and angiogenesis. Phar-macol Rev 2004; 56(4): 549-80.
  33. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, et al. VEGF-D is the strongest angiogenic and lym-phangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 2003; 92(10): 1098-106.
  34. Zhao HC, Qin R, Chen XX, Sheng X, Wu JF, Wang DB, et al. Microvessel density is a prog-nostic marker of human gastric cancer. World J Gastroenterol 2006; 12(47): 7598-603.
  35. Huwer H, Welter C, Ozbek C, Seifert M, Straub U, Greilach P, et al. Simultaneous surgical revas-cularization and angiogenic gene therapy in dif-fuse coronary artery disease. Eur J Cardiotho-racSurg 2001; 20(6): 1128-34.
  36. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney IntSuppl 2000; 77: S113-9.
  37. Al-Harris ES, Al-Janabi AA, Al-Toriahi KM, Yasseen AA. Over expression of vascular endo-thelial growth factor in correlation to Ki-67, grade, and stage of breast cancer. Saudi Med J 2008; 29(8): 1099-104.
  38. Waltenberger J. New Horizons in Diabetes Ther-apy: The Angiogenesis Paradox in Diabetes: De-scription of the Problem and Presentation of a Unifying H ypothesis. Immun. Endoc & Metab.Agents in Med.Chem 2007; 7, 87-93.
  39. Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 2004; 164(6): 1935-47.
  40. Waltenberger J. Impaired collateral vessel devel-opment in diabetes: potential cellular mecha-nisms and therapeutic implications. Cardiovasc Res 2001; 49(3): 554-60.
  41. Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Cir-culation 1999; 99(17): 2239-42.
  42. Boodhwani M, Sodha NR, Mieno S, Xu SH, Feng J, Ramlawi B, et al. Functional, cellular, and molecular characterization of the angiogen-ic response to chronic myocardial ischemia in diabetes. Circulation 2007; 116(11 Suppl): I31-7.
  43. Kivela R, Silvennoinen M, Lehti M, Jalava S, Vihko V, Kainulainen H. Exercise-induced ex-pression of angiogenic growth factors in skeletal muscle and in capillaries of healthy and diabetic mice. CardiovascDiabetol 2008; 7: 13.
  44. Khazaei M, Fallahzadeh A, Sharifi M, Afshar-moghaddam N, HaghjooJavanmardSh, Salehi E.Effects of diabetes on myocardial capillary density and serum biomarkers of angiogenesis in male rats. CLINICS (Article in press) 2011.
  45. Fallahzadeh A, Khazaei M, Sharifi M, Restora-tion of angiogenesis byenalapril in diabetic hindlimb ischemic rats. Biomed Pap Med FacU-nivPalacky Olomouc Czech Repub (Article in press) 2011.
  46. van Golde JM, Ruiter MS, Schaper NC, Voo S, Waltenberger J, Backes WH, et al. Impaired col-lateral recruitment and outward remodeling in experimental diabetes. Diabetes 2008; 57(10): 2818-23.
  47. WernerGS, Ferrari M, Betge S, Gastmann O, Richartz BM, Figulla HR. Collateral function in chronic total coronary occlusions is related to re-gional myocardial function and duration of oc-clusion. Circulation 2001; 104: 2784-90.
  48. Salis MB, Graiani G, Desortes E, Caldwell RB, Madeddu P, Emanueli C. Nerve growth factor supplementation reverses the impairment, in-duced by Type 1 diabetes, of hindlimb post-ischaemic recovery in mice. Diabetologia 2004; 47(6): 1055-63.
  49. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 2007; 101(9): 948-56.
  50. Waltenberger J, Lange J, Kranz A. Vascular en-dothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabe-tes mellitus: A potential predictor for the individ-ual capacity to develop collaterals. Circulation 2000; 102(2): 185-90.
  51. Celik T, Berdan ME, Iyisoy A, Kursaklioglu H, Turhan H, Kilic S, et al. Impaired coronary col-lateral vessel development in patients with pro-liferative diabetic retinopathy. ClinCardiol 2005; 28(8): 384-8.
  52. Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, et al. Decreased cardiac expres-sion of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002; 105(3): 373-9.
  53. Chen S, Ziyadeh FN. Vascular endothelial growth factor and diabetic nephropathy. CurrDiab Rep 2008; 8(6): 470-6.
  54. Raab S, Plate KH. Different networks, common growth factors: shared growth factors and recep-tors of the vascular and the nervous system. ActaNeuropathol 2007; 113(6): 607-26.
  55. Khazaei M, Zarei M, Sharifi MR, Pourshanazari AA ,The effect of maintenance and reversal of DOCA-Salt hypertension on extravasation of macromolecules and serum nitric oxide concen-tration in male rats.Pathophysiology. 2011; 18(3): 201-6
  56. Khazaei M, Moien-Afshari F, Laher I. Vascular endothelial function in health and diseas-es.Pathophysiology. 2008; 15(1): 49-67
  57. Zarei M, Khazaei M, Sharifi MR, Pourshanazari AA. Coronary angiogenesis during experimental hypertension: is it reversible? JRMS 2011; 16(3): 269-75
  58. Kiefer FN, Neysari S, Humar R, Li W, Munk VC, Battegay EJ. Hypertension and angiogene-sis.Curr Pharm Des 2003; 9(21): 1733-44.
  59. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A ran-domized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for meta-static renal cancer. N Engl J Med 2003; 349(5): 427-34.
  60. Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, et al. Vascular endothelial growth factor receptor tyrosine ki-nase inhibitors: PTK787/ZK 222584. SeminOn-col 2003; 30(3 Suppl 6): 32-8.
  61. Khazaei M, Nematbakhsh M. Serum level of vascular endothelial growth factor is increased by estrogen replacement therapy in normoten-sive and DOCA-Salt hypertensive ovariecto-mized rats.ClinChimActa. 2006; 365(1-2): 206-10.
  62. Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG, Lip GY. Endothelial damage and angiogenesis in hypertensive patients: rela-tionship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003; 16(1): 11-20.
  63. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7(3): 193-201.
  64. Yang R, Ogasawara AK, Zioncheck TF, Ren Z, He GW, DeGuzman GG, et al. Exaggerated hy-potensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hy-pertension 2002; 39(3): 815-20.
  65. Berkley KJ, Rapkin AJ, Papka RE. The pains of endometriosis. Science 2005; 308(5728): 1587-9.
  66. Becker CM, D'Amato RJ. Angiogenesis and antiangiogenic therapy in endometrio-sis.Microvasc Res 2007; 74(2-3): 121-30.
  67. Donnez J, Smoes P, Gillerot S, Casanas-Roux F, Nisolle M. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 1998; 13(6): 1686-90.
  68. Mueller MD, Lebovic DI, Garrett E, Taylor RN. Neutrophils infiltrating the endometrium express vascular endothelial growth factor: potential role in endometrial angiogenesis. FertilSteril 2000; 74(1): 107-12.
  69. McLaren J, Prentice A, Charnock-Jones DS, Smith SK. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 1996; 11(1): 220-3.
  70. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM. Identification of functional estrogen response el-ements in the gene coding for the potent angio-genic factor vascular endothelial growth factor. Cancer Res 2000; 60(12): 3183-90.
  71. Hull ML, Charnock-Jones DS, Chan CL, Bruner-Tran KL, Osteen KG, Tom BD, et al. Antiangio-genic agents are effective inhibitors of endome-triosis. J ClinEndocrinolMetab 2003; 88(6): 2889-99.
  72. Griffioen AW, Molema G. Angiogenesis: poten-tials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52(2): 237-68.
  73. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, et al. Nitric oxide synthase modulates angiogenesis in response to tissue is-chemia. J Clin Invest 1998 Jun 1;101(11):2567-78.
  74. Pandya NM, Dhalla NS, Santani DD. Angiogene-sis--a new target for future therapy. Vas-culPharmacol 2006; 44(5): 265-74.
  75. Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ishikura H. Pathophysiology of tumor neovas-cularization. Vasc Health Risk Manag 2005; 1(4): 277-90.
  76. Furuya M, Yonemitsu Y. Cancer neovasculari-zation and proinflammatory microenviron-ments.Curr Cancer Drug Targets 2008; 8(4): 253-65.
  77. Ribatti D, Nico B, Crivellato E, Vacca A. The structure of the vascular network of tumors. Cancer Lett 2007; 248(1): 18-23.
  78. Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y, et al. Vascular gene ex-pression in nonneoplastic and malignant brain. Am J Pathol 2004; 165(2): 601-8.
  79. Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, Zhang M, et al. Alterations in vascular gene expression in invasive breast car-cinoma. Cancer Res 2004; 64(21): 7857-66.
  80. St CB, Rago C, Velculescu V, Traverso G, Ro-mans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000; 289(5482): 1197-202.
  81. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the ma-lignant phenotype.Mol Med Today 2000; 6(8): 324-9.
  82. Bingle L, Brown NJ, Lewis CE. The role of tu-mour-associated macrophages in tumour pro-gression: implications for new anticancer thera-pies. J Pathol 2002; 196(3): 254-65.
  83. Dvorak HF. Angiogenesis. J ThrombHaemost 2005; 3(8): 1835-42.
  84. Sacewicz I, Wiktorska M, Wysocki T, Niewia-rowska J. [Mechanisms of cancer angiogenesis]. PostepyHig Med Dosw (Online) 2009; 63: 159-68.
  85. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005; 201(7): 1089-99.
  86. Nishida N. Angiogenesis in cancer. Vascular Health and Risk Management 2006; 2(3): 213.
  87. Marneros AG. Tumor angiogenesis in melano-ma.HematolOncolClin North Am 2009; 23(3): 431-46.
مجله دانشکده پزشکی اصفهان
دوره 29، شماره 132 - شماره پیاپی 132
فروردین و اردیبهشت 1390
صفحه 312-326

فایل ها

سابقه مقاله

  • تاریخ دریافت: 11 اردیبهشت 1390
  • تاریخ بازنگری: 31 فروردین 1403
  • تاریخ پذیرش: 17 فروردین 1401

هم رسانی

ارجاع به این مقاله

آمار